No CrossRef data available.
Article contents
Pharmaceutical Innovation in Latin America and the Caribbean
Published online by Cambridge University Press: 29 December 2023
Abstract
This study assesses Latin America and Caribbean countries’ capacity to innovate new pharmaceuticals, defined as developing new drugs and vaccines, repurposing existing drugs, and inventing around patents to produce new drug variations. Vaccine innovation includes reengineering existing vaccines, developing new manufacturing methods, and the clinical development of unapproved vaccine candidates initiated elsewhere.
- Type
- Symposium Articles
- Information
- Journal of Law, Medicine & Ethics , Volume 51 , Issue S1: Rethinking Pharmaceutical Policies in Latin America and the Caribbean , Fall 2023 , pp. 148 - 162
- Copyright
- © 2023 The Author(s)
References
Tirole, J., Economics for the Common Good (Princeton: Princeton University Press, 2018).CrossRefGoogle Scholar
Cirera, X. and Maloney, W.F., The Innovation Paradox: Developing-Country Capabilities and the Unrealized Promise of Technological Catch-Up, World Bank Publications, 2017.CrossRefGoogle Scholar
Shadlen, K.C., Coalitions and Compliance: The Political Economy of Pharmaceutical Patents in Latin America (Oxford University Press, 2017).CrossRefGoogle Scholar
Kaiser, R., “Multi-Level Science Policy and Regional Innovation: The Case of the Munich Cluster for Pharmaceutical Biotechnology,” Europena Planning Studies 11 (2003): 841–857.CrossRefGoogle Scholar
Barro, S., “La transferencia de I+D, la innovación y el emprendimiento en las universidades,” Educación superior en Iberoamérica (2015); Fuquen, H.S., and Escobar, E.S. Olaya, “A Technology Transfer Strategy Based on the Dynamics of the Generation of Intellectual Property in Latin-America,” Intangible Capital 14 (2018): 203–252.Google Scholar
Fuquen, H.S., and Olaya Escobar, E.S., “A Technology Transfer Strategy Based on the Dynamics of the Generation of Intellectual Property in Latin-America,” Intangible Capital 14 (2018): 203–252.Google Scholar
Sargent, J. and Matthews, L., “Latin American Universities and Technology Commercialization,” Latin American Business Review 15 (2014): 167–190.Google Scholar
Ivama-Brummell, A.M., et al., “Marketing Authorization and Pricing of FDA-Approved Cancer Drugs in Brazil: A Retrospective Analysis,” Lancet Regional Health 22 (2023).Google ScholarPubMed
Sargent and Matthews, supra note 8.Google Scholar
Ivama-Brummell, et al., supra note 10.Google Scholar
Teran, E., et al., “Streamlining Breast Cancer and Colorectal Cancer Biosimilar Regulations to Improve Treatment Access in Latin America: An Expert Panel Perspective,” Lancet Oncology 23 (2022): e348–e358.Google ScholarPubMed
V. Vargas, M. Rama, and R. Singh, “Pharmaceuticals in Latin America and the Caribbean: Players, Access, and Innovation Across Diverse Models,” 2022, available at <https://openknowledge.worldbank.org/handle/10986/36871> (last visited August 27, 2023).+(last+visited+August+27,+2023).>Google Scholar
Id.
Google Scholar
Id.
Google Scholar
UNESCO, “How Much Does Your Country Invest in R&D?” UNESCO Institute for Statistics (UIS), 2020, available at <http://uis.unesco.org/apps/visualisations/research-and-development-spending/> (last visited August 27, 2023).+(last+visited+August+27,+2023).>Google Scholar
UNESCO Institute for Statistics, UNESCO Statistics (2023).Google Scholar
Kapczynski, A., “The Political Economy of Market Power in Pharmaceuticals,” Journal of Health Politics, Policy and Law 48 (2): 215–239.Google Scholar
Scheinberg, M.A., Felix, P.A.O., Kos, I.A., Andrade, M.D.A., and Azevedo, V.F., “Partnership for Productive Development of Biosimilar Products: Perspectives of Access to Biological Products in the Brazilian Market,” Einstein São Paulo 16 (2018).Google ScholarPubMed
Niosi, J., “Imitation and Innovation New Biologics, Biosimilars and Biobetters,” Technology Analysis and Strategic Management 29 (2017): 251–262; G.E. Gutman and P.J. Lavarello, Biosimilar Corporate Strategies in Argentina During the 2000s: Technological and Organizational Learning for Internationalization (2017).Google Scholar
Id. (Gutman and Lavarello).Google Scholar
Niosi, supra note 20.Google Scholar
US-FDA, “Benznidazole,” available at <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=586517> (last visited August 27, 2023).+(last+visited+August+27,+2023).>Google Scholar
Liddicoat, J., et al., “Repositioning Generic Drugs: Empirical Findings and Policy Implications,” International Review of Intellectual Property and Competition Law 53 (2022): 1287–1322.CrossRefGoogle Scholar
Gadelha, C.A.G., Braga, P.S. da C., Montenegro, K.B.M., and Cesário, B.B., “Access to Vaccines in Brazil and the Global Dynamics of the Health Economic-Industrial Complex,” Cadernos de Saude Publica 36 (2020).Google ScholarPubMed
Más-Bermejo, P.I., et al., “Cuban Abdala Vaccine: Effectiveness in Preventing Severe Disease and Death from COVID-19 in Havana, Cuba; A Cohort Study,” Lancet Regional Health-America 16 (2022): 100366; M.E. Toledo-Romaní, et al., “Safety and Efficacy of the Two Doses Conjugated Protein-Based SOBERANA-02 COVID-19 Vaccine and of a Heterologous Three-Dose Combination with SOBERANA-Plus: A Double-Blind, Randomised, Placebo-Controlled Phase 3 Clinical Trial,” Lancet Regional Health 18 (2023).CrossRefGoogle ScholarPubMed
Nature, “Nature Index 2019 Tables: Countries/territories,” 2022, available at <https://www.natureindex.com/annual-tables/2018/country/all>..>Google Scholar
A. Delich, et al., Las universidades, pilares de la ciencia y la tecnología en América Latina (2018).Google Scholar
Mola, E., et al., “Biotechnology in Cuba: 20 Years of Scientific, Social and Economic Progress,” Journal of Commercial Biotechnology 13 (2006): 1–11.CrossRefGoogle Scholar
R. Hernandez and L. Fernando, Factors That Affect the Ability of Universities to Commercialize Their Patents in a Latin American Country (2020).Google Scholar
Fundación Ciencia y Vida, “Nature Index,” 2017, available at <https://www.nature.com/nature-index/institution-outputs/chile/fundacion-ciencia-y-vida/5c0f7310ccceb275f61ff2f2> (last visited August 27, 2023).+(last+visited+August+27,+2023).>Google Scholar
See Gadelha, et al., supra note 25.Google Scholar
Homma, A., “The Brazilian Vaccine Manufacturers’ Perspective and Its Current Status,” Biologicals 37 (2009): 173–176.CrossRefGoogle ScholarPubMed
Frischtak, C.R., “Science and Innovation in Brazil: Where to Now?” Innovation in Brazil (New Jersey: Routledge, 2019): at 93-119; F.S. Perin and J. Paranhos, The Internationalisation of the Large Brazilian Pharmaceutical Companies, 2022, available at <https://www.open-access.bcu.ac.uk/13308/1/Perin%20and%20Peranhos%20-%20CAFE%20WP%2020%20-%20The%20Internationalisation%20of%20the%20Large%20Brazilian%20Pharmaceutical%20Companies.pdf> (last visited August 27, 2023).Google Scholar
Carracedo, S., et al., “The Landscape of COVID-19 Clinical Trials in Latin America and the Caribbean: Assessment and Challenges,” Revista Panamericana de Salud Pública 44 (2020): e177 (2020).Google ScholarPubMed
Scannell, J.W., Blanckley, A., Boldon, H., and Warrington, B., “Diagnosing the Decline in Pharmaceutical R&D Efficiency,” Nature Reviews Drug Discovery 11 (2012): 191–200.CrossRefGoogle ScholarPubMed
Teran, et al., supra note 12; Lizarraga, A. and Mysler, E., “Similar and Mimics: Latin America Biosimilar Regulations,” International Journal of Rheumatic Diseases 22 (2019): 6–8.CrossRefGoogle ScholarPubMed
See Tirole, supra note 1; C. Barrera and M. Waldman, Vertical Integration, Secrecy, and High Tech Industries (2019); Lage, A., “Connecting Science to Population Health: The ‘Closed Loop’ Approach,” MEDICC Review 9 (2007): 48.Google ScholarPubMed
Newman, D.J. and Cragg, G.M., “Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019,” Journal of Natural Products 83 (2020): 770–803.CrossRefGoogle ScholarPubMed
Dutra, R.C., Campos, M.M., Santos, A.R., and Calixto, J.B., “Medicinal Plants in Brazil: Pharmacological Studies, Drug Discovery, Challenges and Perspectives,” Pharmacological Research 112 (2016): 4–29.CrossRefGoogle ScholarPubMed
J. Medaglia, “New ABS Legislation and Practice in Compliance with the Nagoya Protocol: Current Situation and Perspectives in Costa Rica,” in Global Transformations in the Use of Biodiversity for Research and Development (2022): 117-153; da Silva, M., de Oliveira, D.R., “The New Brazilian Legislation on Access to the Biodiversity (Law 13,123/15 and Decree 8772/16),” Brazilian Journal of Microbiology 49, no. 1 (2018): 1–4.CrossRefGoogle Scholar
See supra note 34.Google Scholar